Show simple item record

dc.contributor.authorOlivera, Pablo A
dc.contributor.authorZuily, Stephane
dc.contributor.authorKotze, Paulo G
dc.contributor.authorRegnault, Veronique
dc.contributor.authorAl Awadhi, Sameer
dc.contributor.authorBossuyt, Peter
dc.contributor.authorGearry, Richard B
dc.contributor.authorGhosh, Subrata
dc.contributor.authorKobayashi, Taku
dc.contributor.authorLacolley, Patrick
dc.contributor.authorLouis, Edouard
dc.contributor.authorMagro, Fernando
dc.contributor.authorNg, Siew C
dc.contributor.authorPapa, Alfredo
dc.contributor.authorRaine, Tim
dc.contributor.authorTeixeira, Fabio V
dc.contributor.authorRubin, David T
dc.contributor.authorDanese, Silvio
dc.contributor.authorPeyrin-Biroulet, Laurent
dc.date.accessioned2021-11-24T16:21:51Z
dc.date.available2021-11-24T16:21:51Z
dc.date.issued2021-12
dc.identifier.issn1759-5045
dc.identifier.others41575-021-00492-8
dc.identifier.other492
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/331030
dc.description.abstractPatients with inflammatory bowel disease (IBD) are at increased risk of thrombotic events. Therapies for IBD have the potential to modulate this risk. The aims of this Evidence-Based Guideline were to summarize available evidence and to provide practical recommendations regarding epidemiological aspects, prevention and drug-related risks of venous and arterial thrombotic events in patients with IBD. A virtual meeting took place in May 2020 involving 14 international IBD experts and 3 thrombosis experts from 12 countries. Proposed statements were voted upon in an anonymous manner. Agreement was defined as at least 75% of participants voting as 'fully agree' or 'mostly agree' with each statement. For each statement, the level of evidence was graded according to the Scottish Intercollegiate Guidelines Network (SIGN) grading system. Consensus was reached for 19 statements. Patients with IBD harbour an increased risk of venous and arterial thrombotic events. Thromboprophylaxis is indicated during hospitalization of any cause in patients with IBD. Disease activity is a modifiable risk factor in patients with IBD, and physicians should aim to achieve deep remission to reduce the risk. Exposure to steroids should be limited. Antitumour necrosis factor agents might be associated with a reduced risk of thrombotic events.
dc.languageen
dc.publisherSpringer Science and Business Media LLC
dc.subjectEvidence-Based Guidelines
dc.subject/692/4020/1503/257
dc.subject/692/4019/592/75
dc.subjectevidence-based-guidelines
dc.titleInternational consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease.
dc.typeArticle
dc.date.updated2021-11-24T16:21:50Z
prism.endingPage873
prism.issueIdentifier12
prism.publicationNameNat Rev Gastroenterol Hepatol
prism.startingPage857
prism.volume18
dc.identifier.doi10.17863/CAM.78475
dcterms.dateAccepted2021-07-05
rioxxterms.versionofrecord10.1038/s41575-021-00492-8
rioxxterms.versionVoR
rioxxterms.licenseref.urihttp://creativecommons.org/licenses/by/4.0/
dc.contributor.orcidZuily, Stephane [0000-0002-9326-6881]
dc.contributor.orcidKotze, Paulo G [0000-0002-9632-6691]
dc.contributor.orcidBossuyt, Peter [0000-0003-4027-7365]
dc.contributor.orcidGhosh, Subrata [0000-0002-1713-7797]
dc.contributor.orcidKobayashi, Taku [0000-0002-2073-4234]
dc.contributor.orcidNg, Siew C [0000-0002-6850-4454]
dc.contributor.orcidPapa, Alfredo [0000-0002-4186-7298]
dc.contributor.orcidRaine, Tim [0000-0002-5855-9873]
dc.contributor.orcidRubin, David T [0000-0001-5647-1723]
dc.contributor.orcidDanese, Silvio [0000-0001-7341-1351]
dc.contributor.orcidPeyrin-Biroulet, Laurent [0000-0003-2536-6618]
dc.identifier.eissn1759-5053
cam.issuedOnline2021-08-27


Files in this item

Thumbnail
Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record